TP53 and familial pancreatic carcinoma: Thus far, most MDM2 inhibitors under preclinical and clinical development target MDM2–p53 binding and are expected to have little or no effect on cancers without functional p53, including most advanced cancers, such as pancreatic cancer, breast cancer, and HCC.